Skeletal involvement secondary to renal function impairment, Fanconi syndrome with hypercalciuria and hyperphosphaturia in OCRL is often encountered. [2] [3] [4] [5] Until now, only supportive therapy with calcium and sodium bicarbonate supplementation has been possible. Bisphosphonates have been useful in treating conditions that promote excessive bone resorption and hypercalcemia, such as Paget's disease, osteoporosis and various malignancies. 7 Recently, the clinical indications for intravenous bisphosphonates have continued to expand. [7] [8] [9] In this report, a male patient with a de novo mutation of OCRL1 received intravenous bisphosphonate (pamidronate disodium), along with recombinant human growth hormone (GH) therapy for severe osteoporosis and GH deficiency. The potential use of pamidronate and/or GH to treat hypophosphatemic rickets as a new aspect of OCRL treatment is highlighted, and renal safety is discussed.
Case Report
A Taiwanese boy with OCRL was followed-up since early infancy. He was the fourth child born to young healthy parents, with a birth weight of 3.13 kg. All three of his elder sisters have normal growth and health. Congenital cataracts and hypotonia were noted after birth. He underwent bilateral lens removal at the age of 2 months, when the diagnosis of Fanconi syndrome was made because of the presence of bicarbonaturia, renal tubular acidosis, generalized aminoaciduria, hyperphosphaturia, and impaired urineconcentrating ability. Marked postnatal growth retardation developed and all growth parameters were below the third percentile after 1.5 years. The patient exhibited a facial appearance with frontal bossing, chubby cheeks, and a fair complexion. He suffered from frequent respiratory infections complicated with sepsis, conjunctivitis, enteritis, recurrent pneumonia that led to chronic lung disease, and urinary tract infections with vesicoureteral reflux (from grade II at 9 years to grade V after 16 years). Tracheostomy was performed at 10 years of age for tracheal polypoid granulomatosis after ineffective broncholaser treatment. At the age of 17.5 years, he was extremely short (83.0 cm in height, and 12.0 kg in weight) and had microcephaly (head circumference of 45 cm). Dysmorphic features included sparse/ hypopigmented hair, frontal bossing, enophthalmos with blue sclerae, cloudy cornea, esotropia, queer eye movements or pendular nystagmus, ear dysplasia, dental dysplasia with oligodontia, full cheeks (Figure 1 ), barrel chest, rocker bottom feet, but no plantar masses. The skin showed a lack of subcutaneous fat, and frequent occurrence of purpura, ecchymosis and dermatitis. His blood pressure was 110/70 mmHg. Unusual repetitive limb movements and irritability or rigidity were noted, but there was no digit or joint swelling. Bone fractures interfered with the rehabilitation program.
Laboratory findings were as follows: hemoglobin, 8.5 g/dL; platelet count, 120 × 10 9 /L; metabolic acidosis (pH 7.167; base excess, -19.8); and impaired renal function (Table) . His thyroid function, liver enzymes, plasma total/free carnitine levels, and serum bilirubin, sodium and potassium were within normal ranges. Secondary hyperparathyroidism was noted, with 8.54 μg/L (7.7-53.5 μg/L) 25-hydroxy-vitamin D and 49.2 nmol/L (60-108 nmol/L) calcitriol. Urinalysis revealed proteinuria (25 mg/dL), glucosuria (0.3 g/ dL), reduced creatinine, and elevated calcium and phosphate excretion (Table) . Roentgenographic studies showed diffuse osteoporosis with old fractures in many ribs, kyphoscoliosis of the thoracolumbar spine, deformity of the thoracic cage, flattening of the lumbar vertebral bodies (Figure 2) , and bilateral angulation of the femoral proximal shaft and neck. Bone scintigraphy showed increased radioisotope uptake over the peripheral bones but an absence of radioactivity over the epiphyseal growth plates of the major joints. Renal ultrasonography revealed increased echogenicity with a small right kidney, moderate right and severe left hydronephrosis with thin renal cortices, dilated calyx, dilated tortuous left ureter, and a huge bladder with trabeculation. Neurogenic bladder and grade II (right) and V (left) vesicoureteral reflux were found after a voiding cystourethrography examination.
Brain magnetic resonance imaging studies showed brain atrophy with ventriculomegaly, and multiple cysts or lacunar infarcts over bilateral periventricular white matter and centrum semiovale, which indicated a demyelinating process. Magnetic resonance urography showed obstructive nephropathy with bilateral hydronephrosis and hydroureter ( Figure 3 ). The level of insulinlike growth factor I (IGF-I) was rather low (11.3 nmol/L; range, 38.1-82.3 nmol/L). His skeletal age was only 6 years. Measurement of bone mineral density (BMD) of the lumbar spine (L1-L4) by dual-energy X-ray absorptiometry showed severe osteoporosis (Table) . Gradual loss of renal function with elevated creatinine and blood urea nitrogen was seen, with reduction of creatinine clearance (CCr) from 21.5 to , and 25% tubular resorption of phosphate (Table) .
His mother has normal renal and liver function, urinalysis and blood pressure. Neither micropunctate nor posterior cortical cataracts could be detected by slit-lamp examination in his mother and three elder sisters. The karyotype of the patient was 46,XY, whereas that of his mother and three sisters was 46,XX. A mutation-insertion of a T base between nucleotides 2282 and 2283 in exon 20 (c.2282_2283insT)-in the OCRL1 gene was identified. This led to a frameshift DNA mutation that resulted in a stop codon mutation (Asp ; TGA) that results in premature termination of translation (D762X) after direct sequencing of the total OCRL1 gene (24 exons) (Figure 4) . No female carriers could be detected in the patient's family.
At the age of 17.5 years, the patient began intravenous pamidronate disodium at a dose of 15 mg/m 2 for 4 hours every month during the next 3 years. Hemogram, urinalysis, and liver/renal function tests were obtained every 2 months. Clinical and laboratory findings before and after pamidronate treatment are shown in the Table. The BMD Z scores increased significantly relative to the baseline, from -7.3 to -3.3 after 3 years treatment, particularly after simultaneous recombinant human GH replacement therapy (0.023 mg/kg/ day, as for GH-deficient patients), via subcutaneous injection from months 18 to 34 (Table) . No further leg fracture occurred after the first course of treatment. Pamidronate was well-tolerated and there were no drug-related adverse events. Daily urinary calcium and phosphate excretion and calcium/creatinine ratio were reduced (Table) and calcitriol level was normalized. Bone metabolism markers and the level of intact parathyroid hormone reduced gradually (Table) . The patient was also treated conservatively with calcium tablets, sodium bicarbonate, folic acid, vitamin B complex and vitamin C, and oral vitamin D3 at the same time. The hemogram showed improvement of hemoglobin level (12.2 g/dL) and platelet count (202 × 10 9 /L). He was noted to have more hair growth and pigmentation, and improved activity, mood and social interaction after these treatments. Often, head turning or shaking persisted even after hypocalcemia had been corrected. He cannot talk but can only make sounds. He has five residual primary teeth (mobile), and can sit alone but cannot stand. He continued on therapy for > 3 years without advanced renal impairment.
Furthermore, CCr was improved from 17.50 to about 30 mL/min/1.73 m 2 and tubular resorption of phosphate from 25% to 54% (Table) .
Discussion
Our patient showed several unusual features, including severe growth retardation, missing teeth with prolonged retention of residual primary teeth, chronic lung disease, recurrent purpuric macules, GH deficiency, and profound osteoporosis. Markedly retarded skeletal age associated with absence of radioactivity over the epiphyseal growth plates by bone scintigraphy, and low IGF-I level indicated early cessation of skeletal development. Repetitive limb movements and irritability or rigidity, which may have been related to the cerebral pathology, were noted even after recovery of hypocalcemia. The improved hemogram is considered to be the result of better appetite and hence intake of food and hematopoiesis after these treatments. The musculoskeletal abnormalities may have developed as secondary consequences of hypotonia, renal tubular acidosis, and generalized aminoaciduria, hypocalcemia and hypercalciuria/hyperphosphaturia. Chronic metabolic acidosis with a reduced renal acid excretory reserve may increase alkali mobilization from the bone and thus promote the development of osteoporosis, joint hypermobility and scoliosis. 3, 5, 10 The initial highly elevated collagen I telopeptide and procollagen I N-telopeptide levels were indicative of severe bone resorption. OCRL is inherited in an X-linked fashion and the reported mutations consist of truncating mutations (frameshift, nonsense and splice site mutations, and large genomic deletions), inframe deletion, and missense mutations.
11 New mutation occurs in about one third to a half of patients, 3, 11, 12 therefore, somatic or germinal mosaicism must be taken into account for genetic counseling in this disease. 11 Opacity and other alterations of the cornea are a major problem in the course of the disease. [1] [2] [3] [4] 11 About 94% of female carriers can be detected using slit-lamp examination for the characteristic lenticular opacity, and all genetically proven non-carriers lack this phenotype. 11 Thus, ophthalmological evaluation may be a reliable first-line method to ascertain the carrier state in OCRL, which can then be confirmed by molecular examination for genetic counseling.
11
The present case provides insight into the effects of pamidronate and GH on bone and kidney, which may prevent or delay skeletal-related events and provide benefits in renal tubular function in OCRL. Intravenous bisphosphonates, which are excreted intact primarily via the kidney, have improved osteoporosis in various pediatric diseases. 9, 13 However, risks of renal adverse reactions after such therapy do exist and may aggravate the preexisting impaired renal function, such as collapsing glomerulopathy or tubulointerstitial inflammatory nephritis. 7, 14, 15 Therefore, it has been suggested that pamidronate infusion is contraindicated in patients with severe renal impairment (CCr < 30 mL/minute), unless in cases of lifethreatening tumor-induced hypercalcemia when the benefit outweighs the potential risk, and such treatment should be withheld until renal function returns to within 10% of the baseline value or serum creatinine is < 1.2 mg/dL. 7, 8, 14, 15 However, from the present case report, monthly infusions of 15 mg/m 2 pamidronate for > 3 years appear to be safe without aggravating renal insufficiency (Table) . Furthermore, certain beneficial long-term effects, including amelioration of hypophosphatemic rickets following Fanconi syndrome, have been noted, as shown by renal function in kidney transplant patients receiving pamidronate for transplantation-associated bone loss. 13 The better outcome of these patients may have resulted from an absence of predisposing malignancies and the inhibitory effect of pamidronate, which is characterized by a decrease in serum calcium and phosphate and a subsequent decrease in their urinary excretion. Glomerular filtration rate can be improved by controlling hyperphosphaturia/hypercalciuria, which can lead to a reduced volume of extracellular fluid. 14, 15 Furthermore, when recombinant human GH was administered together with pamidronate in our patient, more significant improvement of bone turnover parameters and BMD was noted (Table) . Close correlation between increased serum IGF-I levels after GH treatment and increased phosphate reabsorption has been reported, 16, 17 which further explains the mechanism of improved tubular resorption of phosphate/glomerular filtration rate in our patient.
In conclusion, this case report shows that the cyclical administration of intravenous pamidronate has a positive impact on hypophosphatemia and BMD in children with OCRL, particularly with early adjunctive recombinant human GH replacement therapy.
